Seeking Alpha
 

Sequenom, Inc. (SQNM)

- NASDAQ
  • Jan. 9, 2014, 9:11 AM
    | Jan. 9, 2014, 9:11 AM | 3 Comments
  • Jan. 8, 2014, 6:27 PM
    • Sequenom (SQNM) shares surge 10.2% in AH trading after the company announces it has received a patent for "Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing" from the European Patent Office.
    • The company states that it is "the first patent filing made in the EPO directed to such novel methods."
    | Jan. 8, 2014, 6:27 PM | 1 Comment
  • Dec. 27, 2013, 5:50 PM
    | Dec. 27, 2013, 5:50 PM | 6 Comments
  • Nov. 11, 2013, 3:51 PM
    • Sequenom (SQNM -0.2%) gets a vote of confidence from Maxim's Bryan Brokmeier who reiterates the shares at Buy following the company's Q3 results.
    • "The reimbursement environment remains challenging [but] we're increasingly optimistic," Brokmeier notes, citing the percentage of diagnostic revenue from international, the Q/Q rise in covered lives, and the fact that "all major national payers are reimbursing the MaterniT21."
    • Price target is $6.
    | Nov. 11, 2013, 3:51 PM | Comment!
  • Nov. 8, 2013, 12:53 PM
    | Nov. 8, 2013, 12:53 PM | Comment!
  • Nov. 8, 2013, 9:22 AM
    | Nov. 8, 2013, 9:22 AM | 1 Comment
  • Nov. 8, 2013, 8:52 AM
    • Sequenom (SQNM) rallies 24% premarket after reporting Q3 results Thursday evening.
    • Revenues rose 92% Y/Y and 26% sequentially to $44M for the period thanks to "the continued adoption of the MaterniT21 PLUS test."
    • Total tests accessioned: 48,300 (+87% Y/Y). MaterniT21 PLUS patient samples come in at 38,600 — that's +2% Q/Q, as the company notes that "the laboratory increased its focus on tests with acceptable reimbursement."
    • Medicaid tests as a percentage of MaterniT21 PLUS tests accessioned: 21%, down from 26% in Q2 (17% in September).
    • Uncollected amounts outstanding for tests delivered that were not recognized as revenue upon delivery: $46-51M.
    • Annualized run rate for MaterniT21 PLUS test as of quarter's end: 150K+ samples.
    • SQNM notes that "the October 30 summary judgment does not impact the current competitive landscape, as the company has competed without the benefit of the patent being recognized." For more on this, see here. (PR)
    | Nov. 8, 2013, 8:52 AM | Comment!
  • Nov. 7, 2013, 4:12 PM
    • Sequenom (SQNM) Q3: EPS of -$0.19, beats by $0.03.
    • Revenue of $44M (+26% Y/Y), beats by $3.4M. (PR)
    | Nov. 7, 2013, 4:12 PM | Comment!
  • Oct. 31, 2013, 12:45 PM
    | Oct. 31, 2013, 12:45 PM | Comment!
  • Oct. 31, 2013, 10:57 AM
    • Sequenom (SQNM -11.3%) falls hard on news the U.S. District Court for the Northern District of California has invalidated a patent related to fetal cell-free DNA detection.
    • Ultimately, the court ruled in favor of Ariosa Diagnostics in finding that the patent sought to cover a natural phenomenon.
    | Oct. 31, 2013, 10:57 AM | Comment!
  • Oct. 18, 2013, 5:46 PM
    • Top Gainers, as of 5:15 p.m.: SQNM +2.5%. AFSI +2.4%. VNDA +2.2%. CE +1.5%. VJET +1.4%.
    • Top Losers, as of 5:15 p.m: DQ -6.6%. JAH -2.4%. SIX -2.0%. UVXY -2.0%. PENN -1.8%.
    | Oct. 18, 2013, 5:46 PM | Comment!
  • Sep. 23, 2013, 4:27 PM
    • Sequenom (SQNM) hires Jefferies to assist in the evaluation of strategic alternatives for SQNM's Genetic Analysis unit. (PR)
    • For H1, revenues for the business fell 3% Y/Y while sales for the Sequenom CMM diagnostics services segment grew 316%. (PR)
    | Sep. 23, 2013, 4:27 PM | 2 Comments
  • Aug. 21, 2013, 5:37 PM
    | Aug. 21, 2013, 5:37 PM | Comment!
  • Aug. 19, 2013, 5:26 PM
    • Sequenom (SQNM) is planning to reduce its workforce by up to 75 employees as part of "an overall cost reduction effort," the company said in a regulatory filing. (8-K
    • SQNM says the move will save it $10M in compensation-related expenses on an annualized basis.
    • The company also says it plans to book ~$1.2M in severance-related expenses in Q3.
    | Aug. 19, 2013, 5:26 PM | Comment!
  • Aug. 16, 2013, 11:24 AM
    • Shares of Sequenom (SQNM +0.3%) pare losses to trade briefly in positive territory on chatter about a Wedbush note which purportedly says competitors Natera and Ariosa have received letters from the NY Department of Health regarding test processing.
    | Aug. 16, 2013, 11:24 AM | 2 Comments
  • Aug. 9, 2013, 12:05 PM
    • Sequenom (SQNM +5%) pops on chatter that the company will be allowed to pursue a ban of a certain pre-natal test.
    | Aug. 9, 2013, 12:05 PM | 1 Comment
Visit Seeking Alpha's
SQNM vs. ETF Alternatives
Company Description
Sequenom Inc is a molecular diagnostic testing and genetics analysis company which provides molecular diagnostic testing services.
Sector: Healthcare
Industry: Biotechnology
Country: United States